{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:21:46Z","timestamp":1791235306961,"version":"4.1.0"},"reference-count":70,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T00:00:00Z","timestamp":1430697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Lupus"],"published-print":{"date-parts":[[2015,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been shown to be effective and safe compared with warfarin for the treatment of venous thromboembolism (VTE) in major phase III prospective, randomized controlled trials (RCTs), but the results may not be directly generalizable to patients with APS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The primary aim is to demonstrate, in patients with APS and previous VTE, with or without systemic lupus erythematosus (SLE), that the intensity of anticoagulation achieved with rivaroxaban is not inferior to that of warfarin. Secondary aims are to compare rates of recurrent thrombosis, bleeding and the quality of life in patients on rivaroxaban with those on warfarin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Rivaroxaban in antiphospholipid syndrome (RAPS) is a phase II\/III prospective non-inferiority RCT in which eligible patients with APS, with or without SLE, who are on warfarin, target international normalized ratio (INR) 2.5 for previous VTE, will be randomized either to continue warfarin (standard of care) or to switch to rivaroxaban. Intensity of anticoagulation will be assessed using thrombin generation (TG) testing, with the primary outcome the percentage change in endogenous thrombin potential (ETP) from randomization to day 42. Other TG parameters, markers of in\u00a0vivo coagulation activation, prothrombin fragment 1.2, thrombin antithrombin complex and D-dimer, will also be assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>If RAPS demonstrates i) that the anticoagulant effect of rivaroxaban is not inferior to that of warfarin and ii) the absence of any adverse effects that cause concern with regard to the use of rivaroxaban, this would provide sufficient supporting evidence to make rivaroxaban a standard of care for the treatment of APS patients with previous VTE, requiring a target INR of 2.5.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0961203315581207","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T21:12:50Z","timestamp":1430773970000},"page":"1087-1094","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":66,"title":["Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II\/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE"],"prefix":"10.1177","volume":"24","author":[{"given":"H","family":"Cohen","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK"},{"name":"Haemostasis Research Unit, Department of Haematology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Dor\u00e9","sequence":"additional","affiliation":[{"name":"University College London Comprehensive Clinical Trials Unit, Gower Street, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Clawson","sequence":"additional","affiliation":[{"name":"University College London Comprehensive Clinical Trials Unit, Gower Street, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"Hunt","sequence":"additional","affiliation":[{"name":"Department of Haematology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"},{"name":"Department of Haematology, Kings College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Isenberg","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology Research, Division of Medicine, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Khamashta","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, UK"},{"name":"Department of Rheumatology, Kings College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Muirhead","sequence":"additional","affiliation":[{"name":"University College London Comprehensive Clinical Trials Unit, Gower Street, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,5,4]]},"reference":[{"key":"bibr1-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91477-4"},{"key":"bibr2-0961203315581207","doi-asserted-by":"crossref","unstructured":"Khamashta MA (ed.)\n                      Hughes syndrome: Antiphospholipid syndrome.\n                      2nd ed. London: Springer-Verlag, 2006.","DOI":"10.1007\/b136178"},{"key":"bibr3-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1053\/j.mpmed.2006.08.012"},{"key":"bibr4-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1002\/art.21224"},{"key":"bibr5-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.77"},{"key":"bibr6-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1002\/art.24232"},{"key":"bibr7-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035241"},{"key":"bibr8-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01340.x"},{"key":"bibr9-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08753.x"},{"key":"bibr10-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60709-X"},{"key":"bibr11-0961203315581207","first-page":"1737","volume":"7","author":"Pengo V","year":"2009","journal-title":"Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost"},{"key":"bibr12-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"bibr13-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"bibr14-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"bibr15-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.004450"},{"key":"bibr16-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207541"},{"key":"bibr17-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"bibr18-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306638"},{"key":"bibr19-0961203315581207","unstructured":"Xarelto 10 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of first authorization: 30 September 2008, www.emc.medicines.org.uk. (accessed 31 October 2014)."},{"key":"bibr20-0961203315581207","unstructured":"Pradaxa 110 mg hard capsules. Summary of product characteristics (SPC), EU. Boehringer Ingelheim International GmBH. Date of first authorization: 18 March 2008, www.emc.medicines.org.uk (accessed 31 October 2014)."},{"key":"bibr21-0961203315581207","unstructured":"Eliquis (apixaban) 5 mg film-coated tablets. Summary of product characteristics (SPC), EU. Bristol-Myers Squibb-Pfizer. Date of first authorization 18 May 2011, www.emc.medicines.org.uk (accessed 31 October 2014)."},{"key":"bibr22-0961203315581207","unstructured":"NICE technology appraisal guidance (TA256) Published date: May 2012. Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation, http:\/\/www.nice.org.uk\/guidance\/ta256 (accessed 31 October 2014)."},{"key":"bibr23-0961203315581207","unstructured":"NICE technology appraisal guidance (TA261) Published date: July 2012. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. http:\/\/www.nice.org.uk\/guidance\/TA261 (accessed 31 October 2014)."},{"key":"bibr24-0961203315581207","unstructured":"NICE technology appraisal guidance (TA287) Published date: June 2013. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism, http:\/\/www.nice.org.uk\/guidance\/TA287 (accessed 31 October 2014)."},{"key":"bibr25-0961203315581207","unstructured":"NICE technology appraisal guidance (TA327) Published date: December 2014. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and\/or pulmonary embolism, http:\/\/www.nice.org.uk\/guidance\/ta327\/chapter\/1-Guidance (accessed 31 October 2014)."},{"key":"bibr26-0961203315581207","unstructured":"The US Food and Drug Administration approval of Xarelto (rivaroxaban) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm278646.htm (November 2011, accessed 31 October 2014)."},{"key":"bibr27-0961203315581207","unstructured":"The US Food and Drug Administration expansion of the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment, http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm326654.htm (November 2012, accessed 31 October 2014)."},{"key":"bibr28-0961203315581207","unstructured":"The US Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy, http:\/\/www.drugs.com\/newdrugs\/fda-approves-eliquis-apixaban-deep-vein-thrombosis-pulmonary-embolism-4073.html (accessed 31 October 2014)."},{"key":"bibr29-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22066"},{"key":"bibr30-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03117.x"},{"key":"bibr31-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.112243"},{"key":"bibr32-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614109"},{"key":"bibr33-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.2.343.343"},{"key":"bibr34-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(90)90014-J"},{"key":"bibr35-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023153"},{"key":"bibr36-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2008.112243"},{"key":"bibr37-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054444"},{"key":"bibr38-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02900.x"},{"key":"bibr39-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113239"},{"key":"bibr40-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614947"},{"key":"bibr41-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.8.2034.2034"},{"key":"bibr42-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.03.018"},{"key":"bibr43-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1160\/TH08-10-0653"},{"key":"bibr44-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02429.x"},{"key":"bibr45-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08433.x"},{"key":"bibr46-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.029017"},{"key":"bibr47-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"bibr48-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"bibr49-0961203315581207","volume-title":"Basic clinical pharmacokinetics","author":"Winter ME","year":"2004","edition":"4"},{"key":"bibr50-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05324.x"},{"key":"bibr51-0961203315581207","first-page":"738","volume":"62","author":"Loizou S","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"bibr52-0961203315581207","first-page":"215","volume":"68","author":"Harris EN","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"bibr53-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.11.1031"},{"key":"bibr54-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09037.x"},{"key":"bibr55-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1160\/TH06-07-0408"},{"key":"bibr56-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07279.x"},{"key":"bibr57-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2011.08.027"},{"key":"bibr58-0961203315581207","unstructured":"Cohen H, Baglin T. Plasma, plasma products and indications for their use. In: Contreras M (ed.)\n                      ABC of transfusion.\n                      4th ed. Oxford: BMJ Books (Wiley-Blackwell), 2009, pp.40-47."},{"key":"bibr59-0961203315581207","unstructured":"EQ-5D-5L Quality of life questionnaire, www.euroqol.org (accessed 22 January 2013)."},{"key":"bibr60-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-03-0176"},{"key":"bibr61-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32833581a3"},{"key":"bibr62-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651587"},{"key":"bibr63-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2009.11.012"},{"key":"bibr64-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1783"},{"key":"bibr65-0961203315581207","unstructured":"Stata Statistical Software: Release 12. College Station, TX: StataCorp LP."},{"key":"bibr66-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.10.1152"},{"key":"bibr67-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198605013141817"},{"key":"bibr68-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07843.x"},{"key":"bibr69-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90245-6"},{"key":"bibr70-0961203315581207","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504133321504"}],"container-title":["Lupus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203315581207","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0961203315581207","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0961203315581207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:15:49Z","timestamp":1777677349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0961203315581207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,4]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["10.1177\/0961203315581207"],"URL":"https:\/\/doi.org\/10.1177\/0961203315581207","relation":{},"ISSN":["0961-2033","1477-0962"],"issn-type":[{"value":"0961-2033","type":"print"},{"value":"1477-0962","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,4]]}}}